Details for Patent: 11,046,713

Which drugs does patent 11,046,713 protect, and when does it expire?

Patent 11,046,713 protects NUBEQA and is included in one NDA.

This patent has eighty patent family members in thirty-seven countries.

Summary for Patent: 11,046,713

Title:	Androgen receptor modulating compounds
Abstract:	The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
Inventor(s):	Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
Assignee:	Orion Oyj
Application Number:	US16/799,270
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 11,046,713

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes				Y

International Family Members for US Patent 11,046,713

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2493858		301041	Netherlands
European Patent Office	2493858		CA 2020 00020	Denmark
European Patent Office	2493858		LUC00154	Luxembourg
European Patent Office	2493858		PA2020514	Lithuania
European Patent Office	2493858		2020C/514	Belgium
European Patent Office	2493858		122020000030	Germany
European Patent Office	2493858		132020000000064	Italy